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Abstract 
Background 
Providing prognostic information at the time of cancer diagnosis has important implications for 
treatment and monitoring. Although cancer staging, histopathological assessment, molecular 
features, and clinical variables can provide useful prognostic insights, improving risk 
stratification remains an active research area. 
 
Methods and findings 
We developed a deep learning system (DLS) to predict disease specific survival across 10 
cancer types from The Cancer Genome Atlas (TCGA). We used a weakly-supervised approach 
without pixel-level annotations, and tested three different survival loss functions. The DLS was 
developed using 9,086 slides from 3,664 cases and evaluated using 3,009 slides from 1,216 
cases. In multivariable Cox regression analysis of the combined cohort including all 10 cancers, 
the DLS was significantly associated with disease specific survival (hazard ratio of 1.58, 95% CI 
1.28-1.70, p<0.0001) after adjusting for cancer type, stage, age, and sex. In a per-cancer 
adjusted subanalysis, the DLS remained a significant predictor of survival in 5 of 10 cancer 
types. Compared to a baseline model including stage, age, and sex, the c-index of the model 
demonstrated an absolute 3.7% improvement (95% CI 1.0-6.5) in the combined cohort. 
Additionally, our models stratified patients within individual cancer stages, particularly stage II 
(p=0.025) and stage III (p<0.001). 
 
Conclusions 
By developing and evaluating prognostic models across multiple cancer types, this work 
represents one of the most comprehensive studies exploring the direct prediction of clinical 
outcomes using deep learning and histopathology images. Our analysis demonstrates the 
potential for this approach to provide significant prognostic information in multiple cancer types, 
and even within specific pathologic stages. However, given the relatively small number of cases 
and observed clinical events for a deep learning task of this type, we observed wide confidence 
intervals for model performance, thus highlighting that future work will benefit from larger 
datasets assembled for the purposes for survival modeling.  
Introduction 
The ability to provide prognostic information in oncology can significantly impact clinical 
management decisions such as treatment and monitoring. One of the most common systems 
for this purpose is the American Joint Committee on Cancer (AJCC) “TNM” cancer staging 
system, whereby tumors are classified by primary tumor size/extent (T), lymph node 
involvement (N), and the presence or absence of distant metastasis (M). Although TNM staging 
is useful and well-studied, there is room for improvement in some settings, with ongoing efforts 
to develop improved prediction strategies that incorporate information such as clinical 
variables[1,2], genetic information[3,4], and histomorphological features including tumor 
grade[5]. In this regard, computational image analysis of tumor histopathology offers an 
emerging approach to further improve patient outcome predictions by learning complex and 
potentially novel tumor features associated with patient survival. 
 
In recent years, deep learning has been shown to recognize objects[6] and diagnose diseases 
from medical images[7,8] with impressive accuracy. In pathology, prior studies have reported 
deep learning models with performance on par with human experts for diagnostic tasks such as 
tumor detection and histologic grading[8–10]. These models are typically trained on millions of 
small image patches taken from whole-slide images (WSIs) of digitized pathology slides that 
have had specific features of interest labeled by pathologists, often involving detailed, hand-
drawn annotations. The reliance on expert annotation has two notable disadvantages. Firstly, 
these annotations are laborious for experts, requiring hundreds to thousands of hours per 
prediction task of interest and limiting the ability to quickly extend to new applications such as 
other cancer types or histologic features. Secondly, the annotations explicitly enforce that the 
learned morphologic features are correlated with the known patterns being annotated. 
 
By contrast, a different line of work focuses on directly learning morphologic features associated 
with survival without reliance on expert annotation for known pathologic features or regions of 
interest. Such approaches instead provide the machine learning models with a single “global” 
label per slide or case, such as a specimen’s mutational status or a patient’s clinical outcome. 
The task of predicting clinical outcomes from WSIs is particularly challenging due to the large 
size of these images (approximately 100,000×100,000 pixels at full resolution) along with the 
notion that the morphologic features associated with survival may, in principle, appear in any 
part of the imaged tissue. The large amount of image data in conjunction with morphological 
heterogeneity and unknown discriminative patterns result in an especially challenging, “weakly-
supervised” learning problem. 
 
Several prior efforts using machine learning and WSIs to address the survival prediction 
problem have used data from The Cancer Genome Atlas (TCGA), the largest publicly available 
database to our knowledge of digitized WSIs paired with clinical and molecular information[11–
17]. These prior works have used feature-engineering approaches[13,16], leveraged annotated 
regions of interest[12,18,19], focused on learning of known histologic features[17] and/or 
developed models to directly predict survival for an individual cancer type. Here, we build on 
and extend prior work by developing an end-to-end deep learning system (DLS) to directly 
predict patient survival in multiple cancer types, training on whole-slide histopathology images 
without leveraging expert annotations or known features of interest. We test several loss 
functions to address the problem of right-censored patient outcomes, a convolutional neural 
network that is directly optimized to extract prognostic features from raw image data, and an 
image subsampling method to tackle the large image problem. 
 
We evaluated our DLS’s ability to improve risk stratification relative to the baseline information 
of TNM stage, age, and sex for 10 cancer types from TCGA. Though we observed improved risk 
stratification based on the model predictions for several cancer types, effect sizes were difficult 
to estimate precisely due to the limited number of cases and clinical events present in TCGA 
(350-1000 cases and 60-300 events per cancer type). While the results reported here provide 
support for the feasibility of developing weakly supervised deep learning models to predict 
patient prognosis from whole-slide images across multiple cancer types, future work exploring 
and validating the potential of deep learning applications for this task will require larger, clinically 
representative datasets. 
Methods 
Data 
Digitized whole-slide images of hematoxylin-and-eosin- (H&E-) stained specimens were 
obtained from TCGA[20] and accessed via the Genomic Data Commons Data Portal 
(https://gdc.cancer.gov). Images from both diagnostic formalin-fixed paraffin-embedded (FFPE) 
slides and frozen specimens were included. Based on initial experiments as well as differences 
in the proportion of available FFPE images across cancer types (i.e. TCGA studies), both the 
FFPE and frozen WSIs available for each patient were used for training and case-level 
predictions. Each case contained 1-10 slides (median: 2). Clinical data (including approximated 
disease specific survival) were obtained from the TCGA Pan-Cancer Clinical Data Resource[21] 
and the Genomic Data Commons. 
 
Of the TCGA studies for which cancer stage data were available, we chose the 10 studies with 
the highest number of cases and survival events. Clinical stage was used only for ovarian 
serous cystadenocarcinoma (OV), which did not have pathologic stage data available but was 
included given the high number of observed events. Cutaneous melanoma (SKCM) was 
excluded as it was not restricted to primary, untreated tumors[14,22]. Thyroid carcinoma 
(THCA) was excluded because only 14 of 479 cases had an observed event. Cases with 
missing data for either pathologic stage, age, sex, or disease specific survival were excluded 
from evaluation, whereas only cases missing disease specific survival were excluded from 
model development (training and tuning). 
 
For each TCGA study, cases were split into train, tune, and test sets in a 2:1:1 ratio. To ensure 
representative splits given the small number of cases, split assignment was further stratified on 
whether the time of disease specific survival event was observed, and the time-to-event 
(discretized into 3 intervals based on the 25th and 75th percentiles). Across all cancer types, 
4,880 cases (12,095 images) where used for training and tuning. The remaining 1,216 cases 
(3,009 images) where used for evaluation (Table 1). 
 
Deep Learning System (DLS) 
 
Neural Network Architecture  
The core element of our deep learning system (DLS) consisted of multiple convolutional neural 
network (CNN) modules with shared weights, and an average pooling layer that merges image 
features computed by these modules (Figure 1). Our CNN consisted of layers of depth-wise 
separable convolution layers, similar to the MobileNet[23] CNN architecture. The layer sizes and 
the number of layers were tuned for each study via a random grid-search (see Supplementary 
Table S2). We chose this family of architectures because they contain relatively few parameters 
compared to other modern CNN architectures, which speeds up training and helps to reduce the 
risk of overfitting. Each CNN module took as input a randomly selected image patch from the 
slides in each case, such that when multiple patches were sampled, probabilistically at least one 
patch was likely to be informative of the outcome. Specifically, if the frequency of informative 
patches on a slide is p, the probability of not sampling any informative patch in n patches 
decays exponentially with n: (1-p)n, shrinking towards zero with even moderate values of n. This 
approach thus handles the weak label nature of survival prediction on large images, where the 
location of the informative region in the image or set of images is unknown. Furthermore, this 
approach naturally generalizes to multiple slides per case. During each training iteration, the n 
patches were sampled randomly, further ensuring that informative patches were sampled 
across training iterations. 
 
Each patch was of size 256 pixels and was sampled uniformly at random from tissue-containing 
regions within all slides in a case. Early experiments with different patch sizes did not yield 
meaningful improvements. The CNN then extracted image-based features from the patches. A 
top-level average-pooling layer allowed the model to take as input different number of patches 
between training and evaluation. This enabled the use of a smaller number of patches and 
resultant higher case diversity during training, and a more extensive coverage of slides in each 
case with a larger number of patches during evaluation. A final logistic regression layer 
produced a prediction given the output of the average pooling layer.  
 
Survival Loss functions 
We experimented with three different loss functions for training the DLS. Early experiments  
(evaluated on the tune split) showed that the Censored Cross-Entropy described below gave 
the best results (Supplementary Figure S1) and was used for final model training. 
 
The first tested loss function was based on the Cox partial likelihood[24], which is used for fitting 
Cox proportional hazard models but be extended to train neural networks as follows: 
 
where is the event time or time of last follow-up, is an indicator variable for whether the 
event is observed, is the set of whole slide images and is the DLS risk score, each for 
the ith case. In our implementation, we used Breslow's approximation[25] for handling tied event 
times. In principle, the loss for every single example is a function of all cases in the training 
data. In practice, we approximated the loss at each optimization step, by evaluating it over the 
examples in a small batch (n ≤ 128) instead of the entire training dataset. 
 
Our second loss function was an exponential lower bound on the concordance index[26]. The 
concordance index is a common performance metric for survival models that corresponds to the 
probability that a randomly chosen pair of subjects is correctly ordered by the model in terms of 
event times. The concordance index itself is not differentiable, however, Vikas et al.[27] 
proposed the following differential lower bound that can be used for model optimization: 
 
 
Where is the set pairs of examples (i, j) where the ith event is observed and . Similar 
to the Cox partial likelihood, we approximated this lower bound on the concordance index at 
each optimization step by evaluating it over the examples in a small batch (n ≤ 128) instead of 
the entire training dataset. 
 
The final loss function, the censored cross-entropy, is an extension of the standard cross-
entropy loss used for classification models to train survival prediction models with right-
censored data. We modeled survival prediction as a classification problem instead of a 
regression or ranking problem, by discretizing time into intervals and training models to predict 
the discrete time interval in which the event occurred instead of a continuous event time or risk 
score. For examples with observed events, the standard cross-entropy was computed. However 
for censored examples, the time interval in which the event occurs is unknown. Therefore, we 
leverage the information that the event did not occur before the censorship time and maximize 
the log-likelihood of the event occurring in the interval of censorship or thereafter. The full loss 
function can be written as follows: 
 
 
Where is the interval in which the event occurred (for example with observed events) and
is the latest interval whose endpoint is before the time of censorship (for censored examples). 
An important design consideration when using this loss function is how to discretize time. We 
used different percentiles of the time to death distribution for non-censored cases (i.e. quartiles). 
Discretization was done separately for each study to account for the considerable differences in 
survival times across studies (cancer types). To obtain a scalar risk score for evaluation, we 
took the negative of the expectation over the predicted time interval likelihood distribution. The 
negation ensured that higher risk score values indicates higher risk. 
 
Training Procedure 
Training examples consisted of sets of up to 16 image patches per case sampled uniformly from 
tissue across all the slides in that case. Tissue detection using a pixel-intensity-based threshold 
as well as data augmentation via stain normalization followed by color and orientation 
perturbations were both performed as described previously[9]. Training was performed using 
WSIs for both frozen and FFPE specimens. Numerical optimization of network parameters was 
done using the RMSProp optimizer[28] in TensorFlow in a distributed fashion, using 10 worker 
machines with 16 processors each. 
 
For each study, we tuned the hyperparameters by randomly sampling 50 hyperparameter 
configurations and then training one model with each configuration for each of the 10 studies 
(500 models in total). The hyperparameter search space is detailed in Supplementary Table S2. 
 
Evaluation Procedure 
At evaluation we sampled 1024 patches per case, using the same procedure as during training. 
Early empirical studies using the tune set showed no performance benefit from sampling more 
patches. The final models used for evaluation were averaged in a number of ways. First, model 
weights were the exponential moving average of model weights across training steps, with a 
decay constant of 0.999. Next, instead of picking a single best training checkpoint (i.e. a model 
evaluated at particular training step) for each study, we used an ensemble of 50 checkpoints. 
Each model was trained for 500,000 steps and evaluated every 25,000 training steps, yielding 
20 checkpoints per model, and a total of 1,000 checkpoints across 50 hyperparameter settings. 
The 50 checkpoints that achieved the highest c-index on the tune set were selected for the 
ensemble. The final ensemble prediction was the median of the 50 individual predictions. 
 
Survival analysis 
To avoid clinically irrelevant comparisons (e.g. 107 days vs 108 days), survival times were 
discretized from days to months for all analyses. For the Kaplan-Meier analysis, cases were first 
stratified into risk groups within each cancer type by choosing different risk score quantiles as 
thresholds. Stratification per cancer type is important because it ensures that the distribution of 
cancer types is the same across all risk groups. Without doing this it would have been possible 
to see differences in risk groups simply because one risk group contains more cases from 
cancers with a worse prognosis (e.g. OV vs BRCA). For the KM analysis by stage, we repeated 
the same procedure for cases from each stage. 
 
We used Cox proportional hazards regression[29] as both an analytical tool and a predictive 
model. We used it first as an analytical tool for determining which variables were correlated with 
disease-specific survival by fitting multivariable models that include the DLS risk scores and 
baseline variables to our test dataset (Table 2). The pathologic stage was encoded as a 
numeric variable (i.e. 1, 2, 3, 4) in this analysis, because there were insufficient data for using a 
dummy variables for many studies. Age was also treated as a numeric variable. Age was 
divided by 10, so that the hazard ratio corresponds to the increased risk from an additional 10 
years of age at the time of diagnosis. We fit a separate model for each study and a model 
across all studies combined. For the combined model, a dummy indicator variable for the cancer 
type was added. 
 
In the second analysis, where we examined the additional prognostic value of adding the DLS to 
a multivariable model, we needed to control for the natural improvements in model fit with more 
input variables. Thus we used Cox regression as a predictive model, in conjunction with leave-
one-out cross validation (LOO) across test set cases (Table 3). In this analysis, prognosis 
prediction performance was measured using the c-index, an extension of the AUC for binary 
outcomes without censorship[30]. Briefly, the concordance (“c”) index is the number of 
“concordant” pairs (cases that were correctly ordered given the outcome and censorship time) 
divided by all informative pairs. Because different studies (cancer types) had markedly different 
followup periods and median survival times, the c-indices for the “combined” study summed 
concordant pairs and informative pairs solely within the same study. For example, the 
concordance index for the combined studies A and B was calculated as (concordant-pairsA + 
concordant-pairsB) / (informative-pairsA + informative-pairsB).  
 
Statistical analysis 
In Kaplan Meier analysis, survival curves for different groups were compared via a logrank test, 
implemented in the Lifelines python package (version 0.12.0)[31]. Confidence intervals and p-
values for hazard ratios in Cox regression models were computed using Lifelines as well. 
Confidence intervals for the c-index and the delta in c-index between models were generated 
via bootstrapping with 9999 samples. 
 
Heatmap analysis 
Risk heatmaps for patch analysis were generated by running the DLS on a single patch at a 
time to produce patch-level DLS risk scores across entire slides. To generate visualizations for 
pathologist review, patches were sampled based on patch-level risk score from the top 25% and 
bottom 25% from each case. Patches were grouped by case and cases were organized by 
patient-level risk prediction. These organized patches were then reviewed by two pathologists to 
qualitatively evaluate high-level features that may be associated with both the case-level and 
patch-level risk scores. 
Results 
Comparing survival rates in low and high risk groups 
The output of the DLS is a continuous risk score that can be used as a feature for survival 
analysis. To define low and high risk groups, cases were binned into risk quartiles using DLS 
risk scores. Binning was done within each cancer type to ensure that the distribution of cancer 
types within each risk group was the same. A logrank test comparison between the Kaplan-
Meier (KM) curves for the high and low risk groups yielded p<0.001 (Figure 2). 
 
Given the known prognostic significance of stage, we assessed if the DLS could also sub-
stratify patients’ risk within each stage. The resulting Kaplan-Meier curves show that the DLS 
can further sub-stratify patients into low and high risk groups for stage II (p < 0.05) and stage III 
(p < 0.001), but not for stage I or stage IV (Figure 3). 
 
Multivariable analysis of the DLS and clinical metadata  
 
Next, we used multivariable Cox proportional-hazards regression to evaluate the significance of 
the DLS as a predictor of disease specific survival after adjusting for available variables: cancer 
stage, age, and sex. For the combined analysis including all 10 cancer types (i.e. “TCGA 
studies”), where cancer type was included as an indicator variable, the DLS was a significant 
predictor, with a hazard ratio of 1.48 (p<0.0001). To ensure that age and stage were adequately 
controlled for across studies, we further fit a combined model with additional interaction terms 
between the study and stage, and between study and age. In this expanded combined model, 
the p-value for the DLS remained below 0.001. 
 
In subanalysis, for 5 of 10 cancer types, the DLS remained significantly associated with disease 
specific survival (Table 2; p=0.0002 to 0.0257). By contrast, cancer stage was a significant 
predictor in 7 studies, while age and sex were each significant predictors in only one study 
each. 
 
Measuring the added predictive value of the DLS 
The concordance index (or c-index) assesses the goodness-of-fit for survival model by 
calculating the probability of the model correctly ordering a (comparable) pair of cases in terms 
of their survival time. We compared the c-index of Cox-regression models with three different 
feature sets: (1) “DLS”, consisting of the DLS predictions only; (2) “Baseline”, consisting of 
stage, age, and sex; and (3) “Baseline+DLS”, consisting of stage, age, sex, and DLS 
predictions. The c-index results for all cancer types combined and for each cancer type 
individually are summarized in Table 3. For the DLS model, the c-index for all 10 studies 
combined (comparisons across cases from different cancer types were excluded) was 61.1 
(95% confidence interval (CI) [57.2, 65.1]). Within individual studies, the confidence intervals 
were too wide to draw meaningful conclusions due to low case volumes. We interpreted the 
delta in c-index between the “Baseline-only” and the “Baseline+DLS” models as a measure of 
the added predictive value of the DLS over the baseline variables. For all studies combined, the 
c-index delta was 3.7 (95% CI [1.0, 6.5]). 
 
In addition to c-index, we also calculated the area under the receiver operating characteristic 
curve (AUC) for prediction of 5-year disease specific survival. Qualitatively similar results were 
observed, with the combined analysis showing an AUC improvement of 6.4 (95% CI [2.2, 10.8], 
Supplementary Table S4). 
 
Understanding the DLS 
To gain initial insights into the DLS, we first computed the correlation of the DLS predictions with 
the baseline variables of stage, TNM categories, and age. The DLS predictions were not 
correlated with age in any study, but were correlated with stage and T-category in several 
cancer types as well as in the combined analysis (Supplementary Table S5). Next, we analyzed 
the regions of each slide that contributed to the overall case classification by extracting the 
individual patches with the highest and lowest patch-level DLS risk scores for further review. 
Using KIRC as a representative example with a consistently high-performing DLS model, the 
patches with the “most confident” predictions for high or low risk tended primarily to contain 
tumor (Figure 4A-C), whereas patches with more intermediate prediction values tended to be 
non-tumor, such as fat, stroma, and fragmented tissue (Figure 4D). In this analysis, more 
detailed associations of histologic features and patch-level risk predictions were not identified.  
Discussion 
Predicting patient prognosis in oncology underlies important clinical decisions regarding 
treatment and monitoring. In this work, we assessed the potential to improve predictions of 
disease-specific survival using a deep learning system trained without human annotations for 
known morphological features or regions of interest.   
 
A natural question arises as to the value of developing algorithms to predict prognosis 
exclusively from learned features, versus leveraging region-level annotations such as tumor 
grade, nuclear pleomorphism, tumor-infiltrating lymphocytes, or mitotic figures among others. 
One straightforward advantage is to avoid the cost, tediousness, and difficulties associated with 
region-level annotations. Furthermore, the relatively unbiased nature of these weakly 
supervised models potentially enables the learning of previously unknown or unappreciated 
prognostic features. The primary disadvantage, on the other hand, was the increased number of 
cases required to train accurate models given that there was only a single case-level training 
label for each image, such as survival or disease progression. To place the difficulty of this 
problem in context, these labels correspond to 109 pixels per image, often with several images 
per case, making for significantly weaker supervision than in typical image prediction tasks that 
deal with images sized 105-106 pixels. In addition, cancer survival prediction is by nature limited 
to several orders of magnitude less data than typical image classification problems (e.g. 105-106 
images for ImageNet versus 102-103 images here). 
 
The DLS presented in this work learned morphologic features that were predictive of disease-
specific survival in multiple cancer types. While we did not identify any clear trends or 
confounders specific to the cancer types for which the models performed best, future work to 
better understand the effects of sample size, image-specific variables, and disease-specific 
variables on clinical predictions from WSIs will be important for the field. Our solution for weak 
supervision involves a neural network architecture that randomly samples multiple tissue-
containing patches for each case at training time. This sampling approach has three main 
advantages. First, it provides a high probability of seeing patches containing informative 
features in each training iteration, and even more so across training iterations. Second, 
assuming each case contains more than one informative image patch, it substantially expands 
the effective dataset size by increasing the diversity of examples. Third, even uninformative 
patches have a regularization effect on the training. A similar approach has been explored[18] 
though only for tissue microarrays of a single cancer type and using image features from a 
frozen model that was trained on ImageNet. We have provided a more comprehensive analysis 
than prior work by developing and validating our DLS models across multiple cancer types on 
WSIs without region of interest annotations. 
 
In our study, the fact that the DLS output remained significantly associated with disease specific 
survival even after adjusting for age and cancer stage suggests that the DLS learned prognostic 
morphologic features that were independent from these baseline variables. In an effort to better 
understand some of the learned features, we applied the DLS to every image patch on each 
slide to obtain “patch-level prognosis estimates” across the entire image. In this analysis, the 
most confident prognostic regions were comprised primarily of tumor with minimal intervening 
stroma or other obvious histological structures. While other machine learning efforts have 
identified prognostic significance for non-tumor elements[17,32], our observations suggest that 
at least for our specific models, the morphologic features of the tumor appear to be more 
relevant than non-tumor regions. However, elucidating the morphological features that the DLS 
learned to help distinguish between high risk and low risk cases remains an exciting but 
challenging topic for future efforts, and one that will likely require identification of unique 
features for different tumor types. One intriguing hypothesis is that DLS-learned features may 
correspond to previously unappreciated representations of tumor biology in the histology, and 
that underlying biological pathways or molecular mechanisms may be further elucidated via 
focused evaluation of regions highlighted by the DLS. 
 
Though we have presented promising results for a challenging deep learning problem, there are 
several notable limitations to our study. First, despite leveraging data across 10 cancer types 
from the biggest public dataset available (TCGA), each cancer type’s test dataset contained 
fewer than 250 cases and fewer than 100 disease specific survival events, resulting in wide 
confidence intervals that limit statistical conclusions (and highlight the importance of reporting 
model performance confidence intervals when publishing in this field). As such, this work 
represents a proof-of-concept study to refine methods and to better understand the feasibility of 
weakly supervised, direct clinical outcome prediction. While the models did learn prognostic 
signals, these findings require additional development and validation in larger datasets to further 
improve predictions and more accurately estimate effect sizes, let alone to demonstrate clinical 
value. Second, our methods and results are limited to datasets from TCGA, for which there are 
typically a small number of images per case and tumor purity in each image is high[14]. Thus it 
remains to be seen if the random “patch-sampling” approach described here will be effective in 
real-world clinical settings where tumor purity is more variable, sectioning protocols may differ, 
and many slides are typically available for each case. Additionally, while the possible 
confounding effect of treatment differences between patients were not addressed in these data, 
all of the patients in these studies were untreated at the time of tissue sampling and the risk 
stratification on baseline variables shows the expected pattern despite possible differences in 
treatment. We also note that the DLS was only presented with regions of primary, untreated 
tumors (as per TCGA inclusion criteria and sampling). While this potentially allowed learning of 
features associated with the primary tumor such as tumor invasion or grade, the DLS is 
arguably less likely to have learned features associated with additional specimens such as 
lymph nodes, margin regions, or metastatic sites. Indeed, the DLS predictions did correlate with 
the “T” categorization of the TNM staging in the combined analysis, but not with the “N” 
categorization (Supplementary Table S5). Future work using additional slides may be able to 
further inform risk stratification via learning of additional histological features. Lastly, this work 
does not specifically incorporate available molecular information from TCGA, which would likely 
require cancer type-specific molecular analyses and larger datasets. 
 
In conclusion, we have demonstrated promising results for direct prediction of clinical outcomes 
in a weakly-supervised setting, without the use of any region-level expert-annotations for 
training. We hope this work provides useful insights and benchmarks regarding dataset 
requirements and modeling approaches for survival prediction, especially as it relates to use of 
the publicly available TCGA data.  
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Tables 
 
Table 1. Dataset Overview. Our datasets were derived from The Cancer Genome Atlas 
(TCGA). Cases with known disease specific survival (DSS), pathologic stage, age, and sex 
were assigned into train, tune, and test splits in a ratio of 2:1:1. Each TCGA study code refers to 
a cancer type, and “Combined” refers to all 10 studies combined. Cancer stage distribution is 
presented in Supplementary Table S1. 
Study 
Cases DSS Events (%) Slides 
Train Tune Test Train Tune Test Train Tune Test 
BLCA 
(bladder urothelial carcinoma) 
197 98 96 62 (31%) 31 (32%) 30 (31%) 437 205 206 
BRCA 
(breast invasive carcinoma) 
488 247 250 40 (8%) 19 (8%) 20 (8%) 1182 599 631 
COAD 
(colon adenocarcinoma) 
218 110 103 32 (15%) 16 (15%) 13 (13%) 625 313 310 
HNSC  
(head and neck squamous cell 
carcinoma) 
196 99 101 52 (27%) 27 (27%) 28 (28%) 481 250 247 
KIRC 
(kidney renal clear cell 
carcinoma) 
260 130 130 55 (21%) 27 (21%) 27 (21%) 777 395 382 
LIHC 
(liver hepatocellular carcinoma) 
165 83 85 32 (19%) 17 (20%) 18 (21%) 341 165 172 
LUAD 
(lung adenocarcinoma) 
233 115 112 54 (23%) 28 (24%) 26 (23%) 619 283 282 
LUSC 
(lung squamous cell carcinoma) 
219 108 109 45 (21%) 22 (20%) 21 (19%) 542 275 269 
OV 
(ovarian serous 
cystadenocarcinoma) 
272 133 137 151 (56%) 73 (55%) 76 (55%) 607 299 298 
STAD 
(stomach adenocarcinoma) 
198 95 93 48 (24%) 24 (25%) 25 (27%) 464 227 212 
Combined 2446 1218 1216 571 (23%) 284 (23%) 284 (23%) 6075 3011 3009 
  
Table 2. Multivariable Cox proportional hazards regression analysis demonstrates 
association of the deep learning system (DLS) with disease-specific survival. Each 
column header represents one of the input variables for the multivariable analysis, with HR 
indicating the hazard ratio. For the combined analysis, the study was also included as an 
indicator variable (coefficients not shown). Univariable analysis is presented in Supplementary 
Table S2. 
 
Study 
Risk Factor 
DLS Age Male Stage 
HR p HR p HR p HR p 
BLCA 0.75 
[0.45, 1.24] 
0.2636 1.27 
[0.82, 1.98] 
0.2809 1.53 
[0.57, 4.11] 
0.3939 2.30 
[1.37, 3.86] 
0.0016 
BRCA 2.86 
[1.42, 5.76] 
0.0034 1.01 
[0.73, 1.40] 
0.9412 NaN NaN 1.72 
[0.94, 3.12] 
0.0767 
COAD 4.03 
[1.92, 8.44] 
0.0002 0.85 
[0.53, 1.38] 
0.5086 1.18 
[0.38, 3.69] 
0.7769 11.86 
[4.18, 33.66] 
0.0000 
HNSC 2.32 
[1.11, 4.88] 
0.0257 0.93 
[0.63, 1.39] 
0.7338 0.91 
[0.37, 2.20] 
0.8262 2.26 
[1.16, 4.42] 
0.0171 
KIRC 1.88 
[1.23, 2.87] 
0.0035 0.99 
[0.69, 1.42] 
0.9517 0.33 
[0.14, 0.77] 
0.0107 3.20 
[2.02, 5.07] 
0.0000 
LIHC 2.74 
[1.54, 4.86] 
0.0006 1.23 
[0.84, 1.82] 
0.2869 0.99 
[0.32, 3.03] 
0.9809 2.31 
[1.25, 4.24] 
0.0072 
LUAD 1.35 
[0.87, 2.08] 
0.1824 0.78 
[0.56, 1.10] 
0.1546 1.36 
[0.58, 3.17] 
0.4762 2.11 
[1.50, 2.97] 
0.0000 
LUSC 1.97 
[0.90, 4.32] 
0.0894 0.83 
[0.49, 1.39] 
0.4785 1.49 
[0.54, 4.14] 
0.4404 1.48 
[0.91, 2.41] 
0.1162 
OV 1.24 
[0.95, 1.63] 
0.1157 1.26 
[1.02, 1.55] 
0.0326 NaN NaN 1.45 
[0.95, 2.20] 
0.0845 
STAD 1.50 
[0.85, 2.62] 
0.1602 0.96 
[0.69, 1.35] 
0.8318 1.94 
[0.79, 4.76] 
0.1496 2.19 
[1.26, 3.83] 
0.0058 
Combined 1.48 
[1.28, 1.70] 
<0.000
1 
1.07 
[0.96, 1.18] 
0.2221 1.08 
[0.80, 1.48] 
0.6063 2.30 
[1.99, 2.66] 
<0.000
1 
  
Table 3. C-index for Cox regression models using DLS and baseline variables as input. 
(1) deep learning system (“DLS-only”), (2) stage, age, sex (“Baseline-only”), or (3) age, stage, 
sex, and DLS (“Baseline + DLS”). Significant differences based on confidence intervals are 
highlighted in bold.  
Study DLS (1) Baseline (2)  Baseline + DLS 
(3) 
Delta (3 -2) 
BLCA 54.0 [43.3, 64.8] 69.0 [57.4, 80.8] 68.3 [56.0, 80.1] -0.7 [-4.6, 2.8] 
BRCA 72.0 [55.5, 87.3] 64.3 [45.6, 78.3] 71.0 [53.8, 85.7] 6.7 [-7.9, 20.6] 
COAD 70.9 [54.0, 85.4] 80.0 [66.6, 90.9] 91.9 [85.7, 96.6] 11.9 [3.8, 23.1] 
HNSC 58.2 [46.0, 70.0] 49.7 [38.8, 60.4] 64.3 [52.6, 75.0] 14.5 [5.3, 24.6] 
KIRC 71.1 [59.4, 82.5] 85.7 [77.9, 92.4] 85.9 [79.1, 92.2] 0.2 [-3.1, 4.0] 
LIHC 71.3 [53.8, 88.0] 77.3 [62.3, 88.5] 80.1 [67.6, 91.2] 2.8 [-6.1, 12.6] 
LUAD 46.3 [32.5, 59.8] 75.4 [65.1, 84.1] 74.8 [64.6, 83.8] -0.6 [-4.0, 2.7] 
LUSC 62.1 [47.3, 75.4] 55.7 [42.6, 68.6] 60.3 [46.4, 72.7] 4.6 [-8.7, 15.8] 
OV 53.9 [45.2, 62.5] 60.3 [52.6, 67.7] 61.3 [53.4, 68.7] 1.0 [-3.4, 5.8] 
STAD 68.7 [57.8, 78.3] 67.5 [57.5, 77.4] 72.4 [62.3, 81.9] 4.9 [-2.1, 12.0] 
Combined 61.1 [57.2, 65.1] 66.9 [63.1, 70.8] 70.6 [67.1, 74.2] 3.7 [1.0, 6.5] 
  
Figures 
 
Figure 1. Summary of the weakly supervised learning approach for directly predicting 
disease specific survival. For each case, cropped image patches were uniformly sampled 
from tissue-containing areas across all slides available for a given case. Next, image features 
were extracted for each patch by a convolutional neural network (CNN). These patch-level 
features were averaged (on a per-channel basis) and fed to a fully connected layer. Our custom 
loss function divided the follow-up period into four discrete bins depending on right-censorship 
time and outcome (Methods). As such, the model was designed to output a probability 
distribution over discretized survival times.  
 
Figure 2. Kaplan Meier curves for DLS risk groups. To define low and high risk groups, 
cases were binned into risk quartiles using DLS risk scores. Binning was done within each 
cancer type to ensure that the distribution of cancer types within each risk group was the same. 
Different colors represent the different risk groups: green for the low risk (0th -25th percentile); 
yellow for medium risk (25th-75th percentile), and red for high risk (75th-100th percentile). P-values 
were calculated using the binary logrank test comparing the low and high risk groups. 
  
  
Figure 3. Kaplan Meier curves for DLS risk groups within each cancer stage. To define low 
and high risk groups, cases were binned into risk quartiles using DLS risk scores. Binning was 
done within each stage and cancer type. This ensures that for each stage, the distribution of 
cancer types within each risk group was the same. P-values were calculated using the binary 
logrank test comparing the low and high risk groups. 
  
 
 
 
 
Figure 4. Visualization of image patches influencing survival prediction. (A) Example of 
WSI kidney renal clear cell carcinoma (KIRC) predicted to be high risk (left), with the DLS-
predicted “risk heatmap” on the right; red patches correspond to “high-risk” and blue patches to 
“low-risk” patch-level predictions (Methods). (B) “Highest-risk” patches from cases predicted to 
be high-risk. (C) “Lowest-risk” patches from cases predicted to be low-risk. (D) “Lowest-risk” 
patches from cases predicted to be high-risk. For B, C, and D, patches in the same row are from 
the same case and each row represents a different case. 
 
 
Supplementary Information 
Supplementary Table S1. Pathologic Stage distribution for each study. *only clinical stage 
(rather than pathologic stage) was available and used for OV. 
Study 
Stage 
Train Tune Test 
I II III IV I II III IV I II III IV 
BLCA 1 
(0.5%) 
73 
(37.1%) 
62 
(31.5%) 
61 
(31.0%) 
1 
(1.0%) 
26 
(26.5%) 
35 
(35.7%) 
36 
(36.7%) 
0 
(0.0%) 
29 
(30.2%) 
35 
(36.5%) 
32 
(33.3%) 
BRCA 76 
(15.6%) 
286 
(58.6%) 
118 
(24.2%) 
8 
(1.6%) 
45 
(18.2%) 
145 
(58.7%) 
52 
(21.1%) 
5 
(2.0%) 
53 
(21.2%) 
139 
(55.6%) 
52 
(20.8%) 
6 
(2.4%) 
COAD 33 
(15.1%) 
84 
(38.5%) 
65 
(29.8%) 
36 
(16.5%) 
24 
(21.8%) 
40 
(36.4%) 
33 
(30.0%) 
13 
(11.8%) 
19 
(18.4%) 
44 
(42.7%) 
25 
(24.3%) 
15 
(14.6%) 
HNSC 11 
(5.6%) 
33 
(16.8%) 
30 
(15.3%) 
122 
(62.2%) 
5 
(5.1%) 
15 
(15.2%) 
21 
(21.2%) 
58 
(58.6%) 
6 
(5.9%) 
15 
(14.9%) 
21 
(20.8%) 
59 
(58.4%) 
KIRC 132 
(50.8%) 
29 
(11.2%) 
61 
(23.5%) 
38 
(14.6%) 
67 
(51.5%) 
15 
(11.5%) 
27 
(20.8%) 
21 
(16.2%) 
66 
(50.8%) 
12 
(9.2%) 
32 
(24.6%) 
20 
(15.4%) 
LIHC 79 
(47.9%) 
46 
(27.9%) 
39 
(23.6%) 
1 
(0.6%) 
43 
(51.8%) 
21 
(25.3%) 
19 
(22.9%) 
0 
(0.0%) 
47 
(55.3%) 
13 
(15.3%) 
23 
(27.1%) 
2 
(2.4%) 
LUAD 117 
(50.2%) 
57 
(24.5%) 
47 
(20.2%) 
12 
(5.2%) 
69 
(60.0%) 
29 
(25.2%) 
12 
(10.4%) 
5 
(4.3%) 
69 
(61.6%) 
25 
(22.3%) 
13 
(11.6%) 
5 
(4.5%) 
LUSC 113 
(51.6%) 
63 
(28.8%) 
40 
(18.3%) 
3 
(1.4%) 
54 
(50.0%) 
36 
(33.3%) 
17 
(15.7%) 
1 
(0.9%) 
51 
(46.8%) 
42 
(38.5%) 
13 
(11.9%) 
3 
(2.8%) 
OV* 4 
(1.5%) 
19 
(7.0%) 
204 
(75.0%) 
45 
(16.5%) 
3 
(2.3%) 
6 
(4.5%) 
108 
(81.2%) 
16 
(12.0%) 
8 
(5.8%) 
4 
(2.9%) 
102 
(74.5%) 
23 
(16.8%) 
STAD 28 
(14.1%) 
68 
(34.3%) 
83 
(41.9%) 
19 
(9.6%) 
13 
(13.7%) 
26 
(27.4%) 
48 
(50.5%) 
8 
(8.4%) 
12 
(12.9%) 
30 
(32.3%) 
39 
(41.9%) 
12 
(12.9%) 
Combined 594 
(24.3%) 
758 
(31.0%) 
749 
(30.6%) 
345 
(14.1%) 
324 
(26.6%) 
359 
(29.5%) 
372 
(30.5%) 
163 
(13.4%) 
331 
(27.2%) 
353 
(29.0%) 
355 
(29.2%) 
177 
(14.6%) 
  
Supplementary Table S2. Hyperparameter search space (see Methods for usage). 
Hyperparameter Description Values 
Fixation Types Fixation types for slides for 
both training and evaluation 
FFPE, “FFPE and FROZEN” 
Patch size Height and width of each 
image patch 
256 
Patch set size Number of patches sampled 
from a case to form a single 
training example: 
1, 4, 8, 16 
Magnification Image magnification at which 
the patches are extracted 
20X, 10X, 5X 
Number of layers Number of layers used in our 
MobileNet-based architecture 
4, 8, 12 
Base depth Depth of the first convolution 
layer in the MobilNet CNN; 
depth grows by a factor of 
1.25 for every 2 layers in the 
network. 
8, 16 
L2 regularization weight Weight of the L2 loss used for 
regularization 
0.004, 0.0004, 0.00004, 
0.000004 
Initial Learning rate Initial learning rate used for 
the RMSPROP optimizer; 
decay rate was 0.99 every 
20,000 steps. 
0.005, 0.001, 0.0005, 0.0001 
Thresholds Percentile thresholds used for 
binning time in the censored 
cross-entropy loss. 
[50], [25, 75], [25, 50, 75] 
Training dataset Trained on study (cancer-
type) specific data, or 
combined across all cancers 
Combined or cancer-specific 
  
Supplementary Table S3. Univariable Cox analysis (see Table 2 for multivariable 
analysis). 
Study 
Risk Factor 
DLS Age Male Stage 
HR p HR p HR p HR p 
BLCA 0.81 
[0.50, 1.32] 
0.3935 1.31 
[0.91, 1.90] 
0.1516 1.41 
[0.54, 3.70] 
0.4801 2.48 
[1.47, 4.20] 
0.0007 
BRCA 3.86 
[2.15, 6.96] 
0.0000 0.99 
[0.71, 1.38] 
0.9509 NaN NaN 2.62 
[1.54, 4.47] 
0.0004 
COAD 2.09 
[1.21, 3.63] 
0.0087 0.68 
[0.45, 1.03] 
0.0706 0.99 
[0.33, 2.96] 
0.9827 6.66 
[2.76, 16.09] 
0.0000 
HNSC 1.82 
[0.98, 3.40] 
0.0583 0.96 
[0.66, 1.41] 
0.8406 1.07 
[0.47, 2.45] 
0.8706 1.98 
[1.08, 3.64] 
0.0274 
KIRC 2.82 
[1.85, 4.32] 
0.0000 1.14 
[0.86, 1.52] 
0.3466 0.57 
[0.27, 1.22] 
0.1500 3.22 
[2.12, 4.90] 
0.0000 
LIHC 3.26 
[1.93, 5.53] 
0.0000 0.97 
[0.70, 1.35] 
0.8658 0.90 
[0.35, 2.32] 
0.8298 2.60 
[1.52, 4.42] 
0.0004 
LUAD 1.06 
[0.68, 1.65] 
0.7954 0.78 
[0.56, 1.09] 
0.1464 1.35 
[0.62, 2.97] 
0.4505 2.06 
[1.48, 2.85] 
0.0000 
LUSC 1.98 
[0.99, 3.94] 
0.0517 0.93 
[0.58, 1.48] 
0.7615 1.69 
[0.62, 4.62] 
0.3075 1.68 
[1.05, 2.68] 
0.0291 
OV 1.19 
[0.90, 1.55] 
0.2168 1.22 
[0.98, 1.50] 
0.0703 NaN NaN 1.35 
[0.90, 2.03] 
0.1446 
STAD 1.74 
[1.05, 2.90] 
0.0329 0.89 
[0.64, 1.25] 
0.5090 1.86 
[0.78, 4.47] 
0.1636 2.26 
[1.34, 3.82] 
0.0023 
 
  
Supplementary Table S4. AUC for binarized 5-year disease-specific survival (instead of c-
index as in Table 3). In STAD, only 3 cases had at least 5 years of follow-up and survived for 
at least 5 years. 
Study DLS (1) Baseline (2)  Baseline + DLS 
(3) 
Delta (3 -2) 
BLCA 53.1 [31.9, 73.8] 68.3 [46.2, 87.7] 69.9 [50.3, 87.3] 1.6 [-9.5, 14.2] 
BRCA 74.0 [58.7, 87.6] 58.4 [37.3, 75.7] 70.0 [51.3, 85.6] 11.6 [-1.5, 25.0] 
COAD 87.5 [66.7, 100.0] 72.9 [43.3, 97.3] 94.8 [80.0, 100.0] 21.9 [2.7, 41.7] 
HNSC 53.5 [33.5, 73.8] 39.9 [15.4, 66.7] 60.1 [38.2, 82.5] 20.2 [-1.3, 44.8] 
KIRC 72.8 [59.4, 85.1] 84.5 [73.4, 94.1] 87.7 [77.1, 96.3] 3.2 [-1.3, 8.4] 
LIHC 77.6 [56.1, 93.8] 65.6 [41.7, 87.4] 74.1 [52.4, 91.8] 8.5 [-9.4, 27.0] 
LUAD 50.9 [29.6, 70.8] 66.3 [39.4, 89.6] 67.1 [40.8, 90.6] 0.9 [-2.9, 6.2] 
LUSC 61.1 [36.7, 82.0] 65.6 [45.5, 84.0] 76.1 [56.0, 92.9] 10.5 [-8.1, 30.5] 
OV 59.9 [47.6, 72.6] 56.6 [43.1, 68.6] 60.5 [46.3, 72.2] 4.0 [-3.3, 11.3] 
STAD 28.0 [0.0, 65.5] 64.0 [4.1, 100.0] 51.3 [4.1, 100.0] -12.7 [-42.4, 0.0] 
Combined 64.3 [58.0, 70.3] 63.7 [57.1, 70.8] 70.1 [63.8, 76.8] 6.4 [2.2, 10.8] 
 
  
Supplementary Table S5. Correlation of the DLS predictions with clinical variables. 
Spearman’s rank correlation and p-values (with significant values in bold) for correlation of each 
variable with DLS predictions across cancer types. The Spearman’s rank correlation coefficient 
was used to account for different numerical scales of each variable. 
 Stage T N M Age 
BLCA 7.54 (0.465) 15.82 (0.124) 6.69 (0.517) 15.50 (0.132) 6.79 (0.511) 
BRCA 24.39 (0.000) 31.00 (0.000) 12.23 (0.053) 12.16 (0.055) -7.39 (0.244) 
COAD 0.39 (0.969) -0.73 (0.942) 3.80 (0.703) 2.90 (0.771) 3.16 (0.751) 
HNSC 6.42 (0.524) 14.92 (0.136) -1.90 (0.851) -1.54 (0.878) -0.94 (0.926) 
KIRC 29.07 (0.001) 27.77 (0.001) -13.34 (0.130) 5.39 (0.542) 14.11 (0.109) 
LIHC 23.01 (0.034) 24.85 (0.022) -11.14 (0.310) -5.20 (0.636) -12.73 (0.246) 
LUAD -3.30 (0.730) 7.41 (0.438) -4.82 (0.614) 17.33 (0.068) 8.50 (0.373) 
LUSC 8.91 (0.357) 17.99 (0.061) 3.75 (0.699) -5.09 (0.599) 20.55 (0.032) 
OV -5.81 (0.500) N/A N/A N/A N/A 
STAD 22.21 (0.032) -2.08 (0.843) 8.26 (0.431) 27.00 (0.009) -5.93 (0.572) 
Combined 15.55 (0.000) 18.95 (0.000) 1.59 (0.602) 5.46 (0.073) 5.34 (0.079) 
  
Figures 
 
 
 
Supplementary Figure S1. Comparison of loss functions for DLS training.  
We compared three loss functions for DLS training: 1) censored cross-entropy, 2) Cox partial 
likelihood, 3) exponential lower bound on concordance index with the TCGA KIRC dataset. For 
each loss function 3 batch sizes (32, 64, 128) and 4 learning rates (10e-3, 5e-4, 10e-4, 5e-5, 
10e-5 ) were tried. Models were evaluated on the tune split. 
 
 
 
